TET2 and neoplasm: In a subset of AITLs, TET2 or DNMT3A have higher‐than‐expected VAF relative to other mutations or tumor content and are possible founder mutations present in hematopoietic stem/progenitor (HSPC) cells [16, 17, 32, 58, 60, 61, 62, 63].